Referencias

1. Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulsive aggression. Psychiatr Clin North Am 1997; 20: 395-403.
2. Monahan J. Mental disorder and violent behavior: perceptions and evidence. Am Psychol 1992; 47: 511-521.
3. Tardiff K, Sweillam A. Assault, suicide, and mental illness. Arc Gen Psychiatry 1980; 37: 164-169.
4. Rossi AM, Jacobs M, Montelleone M, et al. Violent or fear-inducing behavior associated with hospital admission. Hosp Com Psychiatry 1985; 36: 643-647.
5. Rowner BS, Kafonek S, Filipp L. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986; 143: 1446-1449.
6. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982; 248: 333-335.
7. Mann JJ. Violence and aggression. En: Bloom FE, Kupfer DJ. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, Ltd.; 1995. p. 1919-1928.
8. Germine M, Goddard AW, Woods SW, et al. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992; 32: 457-461.
9. Silver JM. Yudosfky SC, Hales RE. Neuropsychiatric aspects of traumatic brain injury. En: Hales RE, Yudosfky SC. Textbook of Neuropsychiatry. Washington: American Psychiatric Press; 1987. p. 179-190.
10. Elliot FA. Neurological findings in adult minimal brain dysfunction and dyscontrol syndrome. J Nerv Ment Dis 1982; 170: 680-68
11. Delgado C. Evaluación y tratamiento de las alteraciones mentales y del comportamiento en los traumatismos craneales. En: Daño cerebral traumático, neuropsicología y calidad de vida. Madrid: Ed. MAPFRE-Fundación MAPFRE Medicina; 1995. p. 187-209.
12. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiat Clin North Am 1997; 20: 427-451.
13. Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988; 49: 184-188.
14. Olivier B, van Dalen D, Hartog J. A new class of psychoactive drugs: serenics. Drugs Future 1986; 11: 473-99.
15. Ratey JJ, Chandler HK. Serenics: Therapeutic potential in aggression. CNS Drugs 1995; 4: 256-260.
16. Tardiff KJ. Violencia. En: Talbott JA, Hales RE, Yudofsky SC. The American Psychiatric Press Tratado de Psiquiatria. Barcelona: Ancora S.A.; 1989. p. 1025-1044.
17. Kerr IB, Taylor D. Acute disturbed or violent behaviour: principles of treatment. J Psychopharmacol 1997; 11: 271-277.
18. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177-180.
19. Simpson D, Anderson I. Rapid tranquillisation: a questionnaire survey of practice. Psychiat Bull 1996; 20: 149-152.
20. Miczek KA. The psychopharmacology of aggression. En: Iversen LL, Iversen SD, Snyder SH. Handbook of Psychopharmacology, Vol. 19: New directions in behavioral pharmacology. New York: Plenum Press; 1987. p. 183-328.
21. Silver JM, Yudofsky S. Propanolol for aggression: literature review and clinical guidelines. Int Drug Ther Newsletter 1985; 20: 9-12.
22. Yudofsky SC, Silver JM, Schneider SE. Pharmacologic treatments of aggression. Psychiatr Ann 1987; 17: 397-407.
23. Gerlach J, Peacock L. Motor and mental side-effects of clozapine. J Clin Psychiatry 1994; 55 (suppl 9B): 107-109.
24. Su T, Tuskan J, Tsao L, et al. Aggression during drug-free and antipsychotic treatment in inpatients with chronic schizophrenia, using the overt aggression scale. Presented at the American College of Neuropsychopharmacology Meeting, San Juan, PR, 1994.
25. Volavka JL, Zito JM, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia (letter). J Clin Psychopharmacol 1993; 13: 287-289.
26. Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998; 59 (suppl 3): 8-14.
27. Cohen S, Underwood M. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994; 55: 440-444.
28. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243-249.
29. Maiuro RD, Avery DH. Psychopharmacological treatment of aggressive behavior: implications for domestically violent men. Violence Victims 1996; 11: 239-261.
30. Ratey J, Sovner R, Parks A, et al: Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry 1991; 52: 159-162.
31. Colella R, Ratey J, Glaser A. Paramenstrual aggression in a mentally retarded adult ameliorated by buspirone. Int J Psychiatry Med 1992; 22: 351-356.
32. Snaith RP, Taylor CM. Irritability: definition, assessment and associated factors. Ver J Psychiatry 1985; 147: 127-136.
33. Fava M, Rosenbaum JF, Pava J, et al. Anger attacks in unipolar depression: I. Clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993; 150: 1158-1163.
34. Fava M, Nierenberg A, Quitkin F, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychoharmacol Bull 1997; 33: 101-103.
35. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 1992; 12: 27-31.
36. Van der Kolk B, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517-522.
37. Heiligenstein JH, Coccaro EF, Potvin JH, et al. Fluoxetine not associated with increased violence or aggression in controlled clinical trials. Ann Clin Psychiatry 1992; 4: 285-295.
38. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348-351.
39. Markovitz P, Calabrese J, Schulz S, et al. Fluoxetine in the treatment of borderline and schiotypal personality disorders. Am J Psychiatry 1991; 148: 1064-1067.
40. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137-141.
41. Markowitz P, Wagner S. Venlafaxine in the treatment of borderline personality disorder. Psychopharm Bull 1995; 31: 773-777.
42. Davidson J, Roth S, Newman E. Treatment of post-traumatic stress disorder with fluoxetine. J Traumatic Stress 1991; 4: 419-423.
43. Shetatsky M, Greenberg D, Lerer B. A controlled trial of phenelzine in post-traumatic stress disorder. Psychiatry Res 1988; 24: 149-155.
44. Soloff P, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377-385.
45. Cowdry R, Gardner D. Pharmacology of borderline personality disorder. Arch Gen Psychiatry 1988; 45: 111-119.
46. Corrigan PW, Yudofsky SC, Silver JM. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Com Psychiatry 1993; 44: 125-133.
47. Kligman D, Goldberg D. Temporal lobe epilepsy and aggression. J Nerv Ment Dis 1975; 160: 324-341.
48. Worrall EP, Moody JP, Naylor GJ. Lithium in non-manic depressives: antiaggressive effect and red blood cell lithium values. Br J Psychiatry 1975; 126: 464-468.
49. Craft M, Ismail IA, Krishnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial. Br J Psychiatry 1987; 150: 685-689.
50. Sheard M, Marini J, Bridges C, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133: 1409-1413.
51. Caley CHF. The pharmacotherapy of human aggression: a review. J Pharm Pract 1996; IX: 133-143.
52. Bear DM. Neurological perspectives on aggressive behavior. J Neurosci Clin Psychiatry 1991; 49: 13-19.
53. Neppe V. Carbamazepine in the psychiatric patient. Lancet 1982; ii: 334.
54. Alam M, Klass D, Luchins D. Divalproex sodium, valproic acid and carbamazepine in aggression. Presented at the 35th Annual New Clinical Drug Evaluation Unit Program meeting. Orlando, FL, May 31-June 3, 1995.
55. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-522.
56. Stein D, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506-510.
57. Post RM. Time course of clinical effects of carbamazepine. Implications for mechanisms of action. J Clin Psychiatry 1988; 49 (suppl 4): 35-46.
58. Volavka J. Can aggressive behavior in humans be modified by beta-blockers?. Postgrand Med 1988; 29: 163-168.
59. Lang C, Remington D. Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent. J Am Acad Child Adolesc Psychiatry 1994; 33: 265-269.
60. Ratey J, Mikkelsen E, Smith G, et al. Beta-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 1986; 6: 103-107.
61. Ratey JJ, Sorgi P, O`Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53: 41-46.
62. Haspel T. Beta blockers and the treatment of aggression. Harv Rev Psychiatry 1995; 2: 274-281.
63. Kaplan HI, Sadock BJ. Antagonistas de los receptores beta-adrenérgicos. En: Kaplan HI, Sadock BJ. Manual de Farmacoterapia en Psiquiatría. Buenos Aires: Waverly Hispánica; 1993. p. 27-34.
64. Konicki PE, Schulz C. Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior. Psychopharmacol Bull 1989; 25: 556-563.
65. Panksepp J, Lensing P, Leboyer M, Bouvard MP. Naltrexone and other potential new pharmacological treatments of autism. Brain Dysfunct 1991; 4: 281-300.
66. Schipper J, Tulp MTM, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metab Drug Interactions 1990; 8: 85-114.
67. Olivier B, Mos J, Van der Heyden J, et al. Modulatory action of serotonin in aggressive behaviour. En: Bevant P, Cools AR, Archer T. Behavioural pharmacology of 5-HT. Hillsdale: Lawrence Erlbaum; 1989. p. 89-115.
68. Oliver B, Mos J, Raghoebar M, et al. Serenics: pharmacology and metabolism. Eur J Pharmacol 1990; 183: 1402.
69. Van Harten J, Mathlener IS, Raghoebar M. Pharmacokinetics of eltoprazine in healthy male subjects. Drug Metabol Drug Interact 1990; 8: 149-158.
70. Olivier B, Mos J, Raghoebar M, et al. Serenics. Preg Drug Res 1994; 42: 167-308.
71. Verhoeven W, Tuinier S, Sijben N, et al. Eltoprazine in mentally retarded self-injuring patients. Lancet 1992; 340: 1037-1038.
72. Tiihonen J, Hakila P, Paanila J, et al. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet 1993; 341: 307.
73. De Koning P, Mak M, de Vries M, et al: Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo and baseline-controlled multi-centre study. Int Clin Psychopharmacol 1994; 14: 187-194.
74. Moriarty J, Schmitz B, Trimble MR, De Koning P. A trial of eltoprazine in the treatment of aggressive behaviours in two populations: patients with epilepsy or gilles de la tourette`s syndrome. Hum Psychopharmacol 1994; 9: 253-258.
75. Kravitz HM, Fawcett J. Serenics for aggressive behaviors. Psychiatr Ann 1994; 24: 453-459.
76. Mos J, Van Aken HHM, Van Oorschot R, Olivier B. Chronic treatment with eltoprazine does not lead to tolerance in its antiaggressive action, in contrast to haloperidol. Eur Neuropsychopharmacol 1996; 6: 1-7.
77. Tuinier S, Verhoeven WMA, Van den Berg YWM, et al. Modulation of serotonin metabolism in self injurious behaviour; an open study with the HT-1 agonist eltoprazine in mental retardation. Eur J Psychiatry 1995; 9: 226-237.
78. Olza I, Velilla MJ, Paumard C, Bonals A. Tratamiento psicofarmacológico de la conducta agresiva en niños y adolescentes disociales. Rev Psiquiat Infan Juvenil 1998; 3: 194-200.
79. Malone RP, Luebbert J, Pena-Ariet M, et al. The Overt Aggression Scale in a study of lithium in aggressive conduct disorder. Psychopharmacol Bull 1994; 30: 215-218.
80. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo controlled study. J Am Acad Child Adol Psych 1995; 34: 445-453.
81. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-bind and placebo controlled study. J Am Acad Child Adol Psych 1996; 35: 480-490.
82. Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997; 58: 12-15.
83. Davidson J, Kudler H, Smith R, et al. Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259-266.
84. Gadow K, Nolan E, Sprafkin J, et al: School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr 1995; 16: 167-176.
85. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-1080.
86. Constantino JN, Liberman M, Kincaid M. Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatrically hospitalized adolescents: results of an open trial. J Child Adolesc Psychopharmacol 1997; 7: 31-44.
87. Fuller RW. The influence of fluoxetine on aggressive behavior. Neuropsychopharmacol 1996; 14: 77-81.
88. Hellings J, Kelley L, Gabrielli W, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57: 333-336.
89. Yepes L, Balka E, Winsberg B. Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry 1977; 18: 39-52.
90. Zubieta J, Alessi N. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 1992; 12: 346-351.
91. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, dexipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50: 441-447.
92. Campbell M, Perry R, Green WH. Use of lithium in children and adolescents. Psychosomatics 1984; 25: 95-104.
93. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Dis 1997; 27: 313-323.
94. Schreier HA. Risperidone for young children with mood disorders and aggressive behavior. J Child Adol Psychopharmacol 1998; 8: 49-59.
95. Kemph J, DeVane C, Levine G, et al. Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993; 32: 577-581.
96. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12: 322-327.
97. Jeanblanc W, Davis Y. Risperidone for treating dementia-associated aggression. Am J Psychiatry 1995; 152: 1239.
98. Holzer JC, Gitelman DR, Price BH. Efficacy of buspirone in the treatment of dementia with aggression. Am J Psychiatry 1995; 152: 812.
99. .Shankle W, Nielson K, Cotman C. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995; 9: 233-237.
100. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicenter study. Br J Psychiatry 1990; 157: 894-901
101. Rothman CB, Chusid E, Giannini MJ. Mental retardation: behavior problems and psychotropic drugs. NY State J Med 1979; 79: 709-715.
102. Lazarus A. Neuroleptic malignant syndrome and pre-existing brain damage. J Neuropsychiatry 1992; 4: 185-187.
103. Cope N. Psychopharmacologic aspects of traumatic brain injury. En: Horn LJ, Zasler ND. Medical rehabilitation of traumatic brain injury. Philadelphia: Hanley and Belfus, Inc; 1996. p. 573-612.
104. Stanislav SW, Fabre T, Crismon ML, Childs A. Buspirone`s efficacy in organic-induced aggression. J Clin Psychopharmacol 1994; 2: 126-130.
105. Mysiw WJ, Jackson RD. Tricyclic antidepressant therapy after traumatic brain injury. J Head Trauma Rehabl 1987; 2: 34-42.
106. Ricketts R. Goza AB, Ellis CR, et al. Fluoxetine treatment of severe self-injury in young adults with mental retardation. J Am Acad Child Psychiatry 1993; 32: 865-869.
107. Kant R, Smith-Seemiller L, Zeiler D. Treatment of aggression and irritability after head injury. Brain Inj 1998; 12: 661-666.
108. Smith KR, Goulding PM, Wilderman D, et al. Neurobehavioural effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol 1994; 51: 653-660.
109. Yudofsky SC, Williams D, Gormar J. Propanolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 1981; 138: 218-220.
110. Mooney GF, Haas LJ. Effect of methylphenidate on brain injury-related anger. Arch Phys Med Rehabil 1993; 74: 153-160.
111. Miczek KA, Weerts E, Haney M, Tidey J. Neurobiological mechanisms controlling aggression: preclinical developments for pharmacotherapeutic interventions. Neurosci Biobehav Reviews 1994; 18: 97-110.
112. Nurco DN, Ball JC, Shaffer JW, et al. The criminality of narcotic addicts. J Nerv Dis 1985; 173: 94-102.
113. Schiff HB, Sabin TD, Geller A, et al. Lithium in aggressive behavior. Am J Psychiatry 1982; 138: 1346-1348.
114. Ratey JJ, Gordon A. The psychopharmacology of aggression: toward a new day. Psychopharmacol Bull 1993; 29: 65-73.
115. Elie R, Langlois Y, Cooper SF, et al. Comparison of SCH-12679 and thioridazine in aggressive mental retardates. Can J Psychiatry 1980; 25: 484-491.
116. Herrera JN, Sramek JJ, Costa JF, et al. High potency neuroleptics and violence in schizophrenics. J Nerv Mental Dis 1988; 176: 558-561.
117. Dowling-Bruun R. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette`s disorder. Am J Psychiatry 1988; 145: 621-624.
118. Bond AJ, Lader MH. Benzodiazepines and aggression En: Sandler M. Psychopharmacology of Aggression. New York, Raven; 1979. p. 173-182.
119. Van der Bijl P, Roelofse JA. Disinhibitory reactions to benzodiazepines: a review. J Oral Maxillofac Surg 1991; 49: 519-523.
120. Rosenbaum JE, Woods SW, Groves JE, et al. Emergence of hostility during alprazolam treatment. Am J Psychiatry 1984; 141: 792-793.
121. Gardner DL, Cowdry RW. Alprazolam induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142: 98-100.
122. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993; 54 (suppl 10): 49-61.
123. Bond AJ, Curran HV, Bruce M, et al. Behavioural aggression in panic disorder after 8 weeks´treatment with alprazolam. J Affec Dis 1995; 35: 117-123.
124. Tuinier S. Clinical aspects of aggression. En: Swinkels JA, Blijleven W. Depression, anxiety and aggression. Factors that influence the course. Houten: Medical Didactic System; 1990. p. 181-193.
125. Salzman C, Kochansky GE, Shader RI, et al. Chlordiazepoxide induced hostility in small group setting. Arch Gen Psychiatry 1974; 31: 401-405.
126. Kochansky GE, Salzman C, Shader RI, et al. The differential effect of chlordiazepoxide and oxazepam on hostility in a small group setting. Am J Psychiat 1975; 132: 861-863.
127. Brown CR. The use of benzodiazepines in prison populations. J Clin Psychiatry 1978; 39: 114-118.
128. Tollefson GD, Rampey AH Jr, Beasley CM Jr, et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163-169.